10-Q: Lantern Pharma Q3 2025: Reduced Losses Amid Funding Needs

Lantern Pharma reported a narrower net loss in Q3 2025 and advanced its drug pipeline, but faces a going concern risk and requires substantial additional funding.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $13,045,221 from $14,906,013 in the prior year.
• Research and development expenses decreased by 26% to $8,769,305 for the nine months ended September 30, 2025, compared to $11,856,169 in 2024.
• General and administrative expenses increased by 12% to $5,006,427 for the nine months ended September 30, 2025, from $4,463,869 in 2024.
• Cash, cash equivalents, and marketable securities totaled $12,362,576 as of September 30, 2025, down from $24,013,063 at December 31, 2024.
• The company believes its current liquidity will fund operations until at least approximately late June 2026 to mid-August 2026, but requires substantial additional funding.
• Enrollment was completed in the Phase 1a clinical trial for LP-184, and LP-284 is advancing in a Phase 1 clinical trial.
• The company entered into an ATM Sales Agreement in July 2025, selling 212,444 shares for $989,061 gross proceeds in Q3 2025, and an additional 144,204 shares for $634,333 gross proceeds between October 1 and November 12, 2025.
• Stockholders approved a one-time stock option repricing on September 19, 2025, for certain employee and director options, resulting in approximately $285,200 of incremental stock compensation expense.

Sentiment

Score: 4

Explanation: While the company reduced its net loss and made progress in clinical trials, the substantial decrease in cash and working capital, coupled with an explicit going concern warning and the need for significant additional funding, indicates a precarious financial position. Operational advancements are positive, but overshadowed by liquidity concerns.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by approximately $1,860,792 compared to the same period in 2024.
• Cash used in operating activities for the nine months ended September 30, 2025, decreased to $12,884,867 from $13,841,414 in the prior year, indicating improved operational cash burn.
• Net cash provided by investing activities significantly improved to $12,761,027 for the nine months ended September 30, 2025, compared to $77,886 used in the prior year, primarily due to marketable securities redemptions.
• Net cash provided by financing activities increased substantially to $971,781 for the nine months ended September 30, 2025, primarily due to at-the-market (ATM) common stock sales.
• Enrollment was completed in the Phase 1a clinical trial for LP-184, a key development milestone for a drug candidate with potential for multiple solid tumors and CNS cancers.
• LP-284 is advancing in a Phase 1 clinical trial for hematological cancers, and the Antibody Drug Conjugate (ADC) program continues to progress with promising preclinical results from the Bielefeld collaboration.
• The RADR AI platform continues to be leveraged for drug discovery and development, including for ADC optimization, reinforcing the company's data-driven strategy.

Negatives

• Total current assets decreased significantly to $13,461,005 as of September 30, 2025, from $25,247,629 at December 31, 2024.
• Marketable securities decreased substantially to $3,973,090 as of September 30, 2025, from $16,501,984 at December 31, 2024.
• Working capital declined significantly to $9,421,033 as of September 30, 2025, from $20,916,454 at December 31, 2024.
• General and administrative expenses increased by 12% for the nine months ended September 30, 2025, to $5,006,427, reflecting higher business development, investor relations, and professional fees.
• Interest income decreased by 47% for the three months ended September 30, 2025, and by 37% for the nine months ended September 30, 2025, due to lower investment balances.
• Other income, net, decreased significantly by $411,071 for the three months and $468,008 for the nine months ended September 30, 2025, primarily due to decreases in dividend and other investment income.
• The company issued 212,444 shares of common stock under its ATM agreement in Q3 2025 and an additional 144,204 shares post-quarter, indicating ongoing dilution for existing shareholders.
• The stock option repricing resulted in approximately $285,200 of incremental stock compensation expense, which will be recognized over time.

Risks

• The company's ability to secure sufficient funding and alternative sources of funding to support existing and proposed preclinical studies and clinical trials.
• The company's ability to continue as a going concern in the absence of obtaining substantial additional funding, as explicitly stated in the filing.
• Uncertainties regarding the initiation, timing, progress, and results of preclinical studies or clinical trials for any drug candidates.
• The company operates in an industry subject to intense competition, government regulation, and rapid technological change.
• Market value fluctuations of marketable securities due to changes in interest rates, market conditions, and credit risk.
• Reliance on foreign third-party manufacturers and service providers, and potential impacts from changes to U.S. and international trade policies.
• Geopolitical risk, including in Taiwan where clinical testing of LP-300 is being pursued.
• The potential for dilution of existing stockholders' ownership interests if additional capital is raised through equity sales.
• The possibility of restrictive covenants if debt financing is pursued.
• Inflation could increase labor and clinical trial costs, negatively impacting future results of operations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it develops its drug candidates and seeks regulatory approval. It anticipates substantial increases in research and development expenses as clinical trials for LP-300, LP-184, and LP-284 progress, and as new programs are initiated. The company will need substantial additional funding in the near future to complete clinical trials and support operations, with existing funds projected to last until late June 2026 to mid-August 2026.

Management Comments

• "We believe that our cash, cash equivalents, and marketable securities on hand as of the date of this report will enable us to fund our anticipated operating expenses and capital expenditure requirements until at least approximately late June 2026 to mid August 2026."
• "We will need substantial additional funding in the near future, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization efforts."
• "Our ability to continue as a going concern is highly contingent on the ability to raise additional capital for ongoing research and development and clinical trials as we expect to continue incurring losses for the foreseeable future."
• "These factors raise substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding."

Industry Context

Lantern Pharma operates in the highly competitive and rapidly evolving oncology drug development sector, distinguishing itself through an AI-driven approach (RADR platform) to streamline drug discovery and target specific patient populations. This strategy aligns with broader industry trends towards precision oncology and leveraging big data and machine learning to de-risk development and accelerate clinical timelines. The focus on "rescuing" historical drug candidates with AI insights also represents an innovative approach to drug development, aiming to reduce the time and cost associated with traditional methods. The company's pipeline, including small molecules and an ADC program, addresses multiple cancer indications, positioning it within a dynamic and high-growth segment of the biopharmaceutical market.

Comparison to Industry Standards

• The company's AI-driven RADR platform, with over 200 billion data points, aims to reduce the cost and time to bring drug candidates to market, a significant advantage compared to traditional drug development models which often face high failure rates and prolonged timelines.
• The strategy of "rescuing" historical drug candidates, like LP-100 and LP-300, by leveraging AI for biomarker-driven patient stratification, contrasts with conventional development that might abandon compounds after broad Phase 3 trial failures, potentially offering a more efficient path to market for previously overlooked assets.
• The preclinical results for the cryptophycin-ADC, demonstrating picomolar level potency and anti-tumor activity in multiple solid tumor cell lines (including breast, bladder, colorectal, gastric, pancreatic, and ovarian), are competitive within the ADC development space, where high potency and specificity are critical for success.
• The company's financial position, with a going concern warning and reliance on periodic capital raises, indicates a higher risk profile compared to more established, revenue-generating pharmaceutical companies or those with significant non-dilutive funding.

Corporate Governance

Related Party Transactions

• The company holds 13,889 shares of Actuate Therapeutics common stock, valued at approximately $93,000 as of September 30, 2025. Affiliates of Bios Partners, who beneficially own greater than 10% of Lantern Pharma's common stock, also hold substantial beneficial ownership interests in Actuate.

Stakeholder Impact

• Shareholders face potential for significant dilution from ongoing ATM sales and future capital raises. The explicit going concern warning poses a substantial risk to investment value. The stock option repricing could be viewed negatively due to increased compensation expense and potential for further dilution.
• Employees and management may benefit from the stock option repricing, which aims to retain and incentivize them, potentially improving morale and commitment.
• Future patients could benefit from the continued progress in clinical trials for LP-300, LP-184, and LP-284, and the ADC program, which offer potential new cancer therapies.
• Creditors face increased risk due to the company's going concern warning and its reliance on future capital raises to sustain operations.

Next Steps

• Advance and optimize development plans for multiple future LP-184 clinical studies following Phase 1a results.
• Continue to advance LP-284 in its Phase 1 clinical trial.
• Continue preclinical research optimization for the Antibody Drug Conjugate (ADC) program.
• Strategically evaluate drug candidates on a program-by-program basis for further clinical development, either internally or with licensing partners, to maximize commercial opportunity.
• Pursue periodic capital raises and apply for grant funding to support capital needs.
• Potentially explore additional equity offerings and commercial credit facilities for liquidity.
• Continue to build the infrastructure necessary to support expanded operations, preclinical studies, clinical trials, and potential commercialization.
• Continue to develop, maintain, and expand the RADR platform.

Key Dates

Recommendation

While the company has made operational progress in its clinical pipeline and reduced its net loss, the significant decline in cash and working capital, coupled with an explicit "going concern" warning, presents substantial financial risk. The ongoing reliance on dilutive ATM sales for funding is a concern. An investor should "hold" to monitor the company's ability to secure necessary funding and achieve critical clinical milestones, as these factors will heavily influence future valuation. The scientific advancements are promising, but the financial stability is currently too uncertain for a "buy" recommendation, and the pipeline potential prevents a "sell" at this stage.

Keywords

Oncology, Cancer therapies, Artificial intelligence (AI), Machine learning, Drug discovery, Clinical trials, Biomarker-driven, LP-300, LP-184, LP-284, ADC program, RADR platform, Biopharmaceutical, SEC filing, 10-Q, Lantern Pharma